CORTICOSTEROID RANDOMISATION AFTER SIGNIFICANT HEAD INJURY
Not Applicable
Completed
- Conditions
- -F078 Other organic personality and behavioural disorders due to brain disease, damage and dysfunctionOther organic personality and behavioural disorders due to brain disease, damage and dysfunctionF078
- Registration Number
- PER-095-03
- Lead Sponsor
- ONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients 16 years of age and older are eligible, with cranial trauma in which, in the absence of sedation, they obtain a score of 14 or less in the first 8 hours of the trauma. Although it is allowed to admit patients up to a maximum of 8 hours post-trauma.
Exclusion Criteria
The routine exclusion of patients with gastrointestinal disorders or pregnancy is unnecessary, unless the responsible physician considers that there is a definitive contraindication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie corticosteroid efficacy in traumatic brain injury (TBI) patients with F078 behavioral disorders?
How do corticosteroids compare to standard-of-care treatments like IV fluids in improving Glasgow Coma Scale outcomes for severe TBI?
Which biomarkers (e.g., S100B, GFAP) predict corticosteroid response in patients with F078 due to head trauma?
What are the long-term adverse events of corticosteroid use in TBI patients, and how do they impact recovery trajectories?
Are there alternative neuroprotective agents or combination therapies (e.g., NSAIDs, edaravone) showing superior outcomes to corticosteroids in post-TBI inflammation management?